- Home
- ORKA
ORKA
Oruka Therapeutics Inc. Common Stock
as 11-15-2024 4:00pm EST
Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | WESTMINSTER |
| Market Cap: | 1.0B | IPO Year: | N/A |
| Target Price: | $43.60 | AVG Volume (30 days): | 139.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $18.72 - $53.88 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Oruka Therapeutics Inc. Common Stock News
ORKA Breaking Stock News: Dive into ORKA Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
13 days ago
Oruka Therapeutics to Present at Multiple November Investor Conferences
GlobeNewswire
2 months ago
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
GlobeNewswire
2 months ago
Oruka Therapeutics Announces $200 Million Private Placement
GlobeNewswire
2 months ago
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
GlobeNewswire
2 months ago
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
Compare ORKA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ORKA Oruka Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.